Aclaris Therapeutics (ACRS) Operating Expenses (2014 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly Operating Expenses of $24.2 million for Q1 2026, up 23.79% year-over-year from $19.5 million in Q1 2025, and up 0.66% quarter-over-quarter from $24.0 million in Q4 2025.
Aclaris Therapeutics (ACRS) Operating Expenses (2014 - 2026) Analysis & Trends
Aclaris Therapeutics' Operating Expenses history runs 13 years deep, the most recent figure standing at $24.2 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 23.79% year-over-year to $24.2 million; the TTM figure through Mar 2026 stood at $88.8 million (down 44.07% YoY), while the FY2025 annual figure was $84.2 million, down 47.59% from the prior year.
- Operating Expenses for Q1 2026 stood at $24.2 million, up from $24.0 million in the prior quarter.
- The five-year high for Operating Expenses was $108.9 million in Q4 2024, with the low at $14.8 million in Q3 2024.
- The 5-year median for Operating Expenses is $22.5 million (2022), against an average of $30.4 million.
- The sharpest annual moves came in 2024 and 2025: Operating Expenses jumped 403.71% in 2024, then plunged 77.93% in 2025.
- Aclaris Therapeutics' Operating Expenses stood at $36.8 million in 2022, then sank by 41.31% to $21.6 million in 2023, then surged by 403.71% to $108.9 million in 2024, then slumped by 77.93% to $24.0 million in 2025, then increased by 0.66% to $24.2 million in 2026.
- Business Quant data shows ACRS's Operating Expenses at $24.2 million in Q1 2026, $24.0 million in Q4 2025, and $20.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | 25.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.87 Mn |
| Mar 31, 2026 | 24.19 Mn |
| Dec 31, 2025 | 24.03 Mn |
| Sep 30, 2025 | 20.45 Mn |
| Jun 30, 2025 | 20.19 Mn |
| Mar 31, 2025 | 19.54 Mn |
| Dec 31, 2024 | 108.89 Mn |
| Sep 30, 2024 | 14.82 Mn |
| Jun 30, 2024 | 15.62 Mn |
| Mar 31, 2024 | 21.33 Mn |
| Dec 31, 2023 | 21.62 Mn |
| Sep 30, 2023 | 40.86 Mn |
| Jun 30, 2023 | 33.68 Mn |
| Mar 31, 2023 | 32.45 Mn |
| Dec 31, 2022 | 36.83 Mn |
| Sep 30, 2022 | 39.89 Mn |
| Jun 30, 2022 | 22.52 Mn |
| Mar 31, 2022 | 20.36 Mn |
| Dec 31, 2021 | 24.39 Mn |
| Sep 30, 2021 | 21.95 Mn |